DelveInsight launched a new report on Trastuzumab Biosimilar Insights 2023.
DelveInsight’s, “Trastuzumab Biosimilar Insight, 2023” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture which may contain the antibiotic gentamicin. Gentamicin is not detectable in the final product. Herceptin (trastuzumab) for injection is a sterile, white to pale yellow, preservative-free lyophilized powder with a cake-like appearance, for intravenous administration.
Click here and get access to free sample pages of the report
Trastuzumab Biosimilars Marketed Drugs
- Kanjinti: Amgen
- Herzuma: Celltrion
Trastuzumab Emerging drugs:
- EG12014: EirGenix
- HD201: Prestige BioPharma
Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/trastuzumab-biosimilars-insight
Table of contents:
1. Key Insights
2. Trastuzumab Biosimilars: Snapshot
3. Executive Summary
4. Regulatory Outlook For Biosimilars
5. Trastuzumab (Reference Product: Herceptin)
6. Research and Development
7. Herceptin Biosimilar: Emerging Opportunities
8. Trastuzumab: Biosimilars Assessment
9. Trastuzumab Biosimilars Profiles: By Company
10. Trastuzumab Biosimilars: Comparative Landscape: By Company
11. Trastuzumab Biosimilars: Competitive Landscape
12. Market Drivers
13. Market Barriers
14. SWOT Analysis
15. Appendix
16. Bibliography
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
Download our full report: https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/